Antiretroviral therapy during pregnancy and early neonatal life: consequences for HIV-exposed, uninfected children

AUTOR(ES)

El Beitune, Patrícia, Duarte, Geraldo, Quintana, Silvana Maria, Figueiró-Filho, Ernesto A., Marcolin, Alessandra Cristina, Abduch, Renata

FONTE

Brazilian Journal of Infectious Diseases

DATA DE PUBLICAÇÃO

2004-04

RESUMO

Women have emerged as the fastest growing human immunodeficiency virus (HIV) infected population worldwide, mainly because of the increasing occurrence of heterosexual transmission. Most infected women are of reproductive age and one of the greatest concerns for both women and their physicians is that more than 1,600 infants become infected with HIV each day. Almost all infections are a result of mother-to-child transmission of HIV. With the advent of combination antiretroviral therapies, transmission rates lower than 2% have been achieved in clinical studies. Antiretroviral compounds differ from most other new pharmaceutical agents in that they have become widely prescribed in pregnancy in the absence of proof of safety. We reviewed antiretroviral agents used in pregnant women infected with human immunodeficiency virus, mother-to-child transmission, and their consequences for infants.

Documentos Relacionados

• Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in HIV-exposed, uninfected newborn infants
• Immune development in HIV-exposed uninfected children born to HIV-infected women
• Feeding of HIV-exposed children in a city in south of Brazil: family capability, clinical and social conditions
• HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy
• Production of resistant HIV mutants during antiretroviral therapy